Engineered proteins form the basis of biologic medicines, yet most candidates fail during development. Researchers now use AI to predict protein structures and optimize molecular interactions. This shift reduces the cost and time of early-stage discovery. Practitioners can now iterate on drug candidates in silico before entering expensive lab trials.